ClinicalTrials.Veeva

Menu

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) (MERIT)

Roche logo

Roche

Status and phase

Completed
Phase 2

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Treatments

Drug: Erlotinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT02774278
2004-005096-42 (EudraCT Number)
BO18279

Details and patient eligibility

About

This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death.

Enrollment

264 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Advanced NSCLC
  • Tumor accessible for biopsy by bronchoscopy
  • Disease progression following course of standard chemotherapy, or participants unwilling/unable to undergo chemotherapy

Exclusion criteria

  • Unstable systemic disease
  • Any other malignancies in the last 5 years
  • Brain metastases
  • Previous treatment with therapy acting on the epidermal growth factor receptor (EGFR) axis

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

264 participants in 1 patient group

Erlotinib
Experimental group
Description:
Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.
Treatment:
Drug: Erlotinib

Trial contacts and locations

29

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems